(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Oldest evidence of human fire-making discovered at site in England - 2Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
- 3Pick Your Favored kind of salad
- 46 Novice Cameras for 2024: Ideal for New Picture takers
- 510 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- People are getting their news from AI – and it’s altering their views
- Exhaustive Experiences into Prudent Senior Living in the UK
- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
